DECLARE-TIMI 58
2019
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
In 17,160 patients with type 2 diabetes, dapagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.
Result
Efficacy: CV death/HF hospitalisation and MACE (co-primary)HR 0.83
Below 1 favours dapagliflozin, above 1 favours placebo.
Also reported: MACE not significantly reduced.
- Subtopic
- SGLT2 inhibitors
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 CCSESC 2023 DiabetesACC/AHA 2023 CCDACC/AHA 2019 Primary PreventionACC/AHA 2026 CKM
- Source
- Wiviott SD, et al. N Engl J Med. 2019;380(4):347-357.doi 10.1056/NEJMoa1812389
Discussion & critique
The largest SGLT2i outcomes trial, with the most primary-prevention patients: benefit was mainly heart-failure prevention rather than atherothrombotic events.